All Events

Upcoming Events

10904 0 Quality Assurance - JZero Technical Test - UK Test event 01 (20180219) Quality Assurance - JZero Technical Test - UK Test event 01 (20180219) UK uk-UA 23 Feb 2018 23 Feb 2018 23 Feb 2018 23 Feb 2018 13:00:00 14:00:00 Greenwich Mean Time Event Location (Ref# 17) xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx <table border="0" cellpadding="1" cellspacing="1" style="border:1px solid #000000; width:100%"> <tbody> <tr> <td style="text-align:center">Adverse events should be reported. Reporting forms and infromation can be found at <a href="https://yellowcard.mhra.gov.uk/">www.mhra.gov.uk/yellowcard</a>. Adverse events should also be reported to MSD Drug Safety Department on 01992 467272.</td> </tr> </tbody> </table> Master In Progress Local Job Code (Ref# 51) N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 35154 Test Agenda 1 13:00:00 1746 1 Speaker 1 - [ ref# 25.1 / .2 / .3 ] ref# 28 X Speaker 1 [Biography] - ref# 27 xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxxx xxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx Speaker 1 [Short Description] - ref# 26 Xxxx xx http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/ref9_speaker.jpg http://en.wikipedia.org/wiki/Torii http://webcast-editor-tool3.msd.com/filesdownload/SpeakersBio/ON24 PrintInvitation 20141224 Spain(L).pdf 1746 Speaker 1 - [ ref# 25.1 / .2 / .3 ] ref# 28 X Speaker 1 [Biography] - ref# 27 xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxxx xxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx Speaker 1 [Short Description] - ref# 26 Xxxx xx http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/ref9_speaker.jpg http://en.wikipedia.org/wiki/Torii http://webcast-editor-tool3.msd.com/filesdownload/SpeakersBio/ON24 PrintInvitation 20141224 Spain(L).pdf 10906 0 Quality Assurance - JZero Technical Test - UK Test event 02 (20180219) Quality Assurance - JZero Technical Test - UK Test event 02 (20180219) UK uk-UA 27 Feb 2018 27 Feb 2018 27 Feb 2018 27 Feb 2018 13:00:00 14:00:00 Greenwich Mean Time Event Location (Ref# 17) xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx <table border="0" cellpadding="1" cellspacing="1" style="border:1px solid #000000; width:100%"> <tbody> <tr> <td style="text-align:center">Adverse events should be reported. Reporting forms and infromation can be found at <a href="https://yellowcard.mhra.gov.uk/">www.mhra.gov.uk/yellowcard</a>. Adverse events should also be reported to MSD Drug Safety Department on 01992 467272.</td> </tr> </tbody> </table> Master In Progress Local Job Code (Ref# 51) N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 35156 Test Agenda 1 13:00:00 1746 1 Speaker 1 - [ ref# 25.1 / .2 / .3 ] ref# 28 X Speaker 1 [Biography] - ref# 27 xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxxx xxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx Speaker 1 [Short Description] - ref# 26 Xxxx xx http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/ref9_speaker.jpg http://en.wikipedia.org/wiki/Torii http://webcast-editor-tool3.msd.com/filesdownload/SpeakersBio/ON24 PrintInvitation 20141224 Spain(L).pdf 1746 Speaker 1 - [ ref# 25.1 / .2 / .3 ] ref# 28 X Speaker 1 [Biography] - ref# 27 xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxxx xxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx Speaker 1 [Short Description] - ref# 26 Xxxx xx http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/ref9_speaker.jpg http://en.wikipedia.org/wiki/Torii http://webcast-editor-tool3.msd.com/filesdownload/SpeakersBio/ON24 PrintInvitation 20141224 Spain(L).pdf 11472 0 Quality Assurance - JZero Technical Test - MCI + VEC Launching Test Quality Assurance - JZero Technical Test - MCI + VEC Launching Test UK uk-UA 09 May 2018 09 May 2018 09 May 2018 09 May 2018 01:00:00 23:55:00 British Summer Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. National Webcast live from Cambridge</div> At this interactive event, you will hear an expert panel share case studies and review strategies for patient selection and effective treatment sequencing when managing advanced melanoma patients using modern immunotherapies and BRAF targeted agents. As a result of attending this event you should be better prepared to: <ul> <li>Evaluate clinical data currently used for treating advanced melanoma</li> <li>Select treatment based on patient and disease characteristics</li> <li>Sequence treatment to optimise patient outcomes</li> <li>Manage challenges associated with treatment selection and sequencing in advanced melanoma</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudamelanoma.pdf">Click here </a>for Prescribing Information</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. National Webcast live from Cambridge At this interactive event, you will hear an expert panel share case studies and review strategies for patient selection and effective treatment sequencing when managing advanced melanoma patients using modern immunotherapies and BRAF targeted agents. As a result of attending this event you should be better prepared to: Evaluate clinical data currently used for treating advanced melanoma Select treatment based on patient and disease characteristics Sequence treatment to optimise patient outcomes Manage challenges associated with treatment selection and sequencing in advanced melanoma Click here for Prescribing Information <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress ONCO-1246506-0009 Date of preparation: April 2018 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage_10900.gif 26 Webconference 26 Webconference 2 Commercial - Unbranded 36217 Chairman address and welcome 01:00:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 36218 Current treatment landscape Advanced Melanoma 01:00:00 35294 3 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 36219 Case studies: Exploring Patient Selection and Sequencing Approaches in Advanced Melanoma 01:00:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 18672 2 Professor Paul Lorigan Professor Lorigan leads a research based clinical practice, specialising in developing new treatments for malignant melanoma. He is Chair of Melanoma Focus (www.melanomafocus.org), the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He also chairs the EORTC Melanoma Group Advanced Disease Subgroup and previously he chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012.   Professor Paul Lorigan Professor of Medical Oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PLorigan.jpg 35294 3 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 36220 Discussion and Q&A 01:00:00 36221 Closing remarks 01:00:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 36222 Close meeting 01:00:00 18669 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 18672 Professor Paul Lorigan Professor Lorigan leads a research based clinical practice, specialising in developing new treatments for malignant melanoma. He is Chair of Melanoma Focus (www.melanomafocus.org), the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He also chairs the EORTC Melanoma Group Advanced Disease Subgroup and previously he chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012.   Professor Paul Lorigan Professor of Medical Oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PLorigan.jpg 35294 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 11086 0 Simponi (Golimumab) in Ulcerative Colitis: Sharing Real World Evidence and Experience Simponi (Golimumab) in Ulcerative Colitis: Sharing Real World Evidence and Experience UK uk-UA 16 May 2018 16 May 2018 16 May 2018 16 May 2018 19:00:00 20:15:00 British Summer Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. </div> <div style="text-align:center">The objective of this event is ‘´To share the real world evidence and experience of Simponi in Ulcerative Colitis´´ which will allow delegates to gain an understanding of the effectiveness of Simponi in a ‘real-world´ setting. <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td> <div>Simponi (Golimumab) is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies.</div> </td> </tr> </tbody> </table> </div> <div style="text-align:center"> <a href="http://www.msdproduct.co.uk/api/simponi.pdf">Click here </a>for Prescribing Information</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. The objective of this event is ‘´To share the real world evidence and experience of Simponi in Ulcerative Colitis´´ which will allow delegates to gain an understanding of the effectiveness of Simponi in a ‘real-world´ setting. Simponi (Golimumab) is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. Click here for Prescribing Information <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td> <div>Simponi (Golimumab) is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies.</div> </td> </tr> </tbody> </table> <div style="text-align:center">  <a href="http://www.msdproduct.co.uk/api/simponi.pdf">Click here </a>for Prescribing Information</div> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GAST-1245435-0007 Date of preparation: March 2018 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage_11086.gif http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage_11086.gif 26 Webconference 26 Webconference 2 Commercial - Unbranded 35503 Welcome and Introduction 19:00:00 18700 1 Dr Mark Samaan Mark gained experience as a clinician and researcher at specialist IBD centres in England, The Netherlands, Canada and the US, working under widely recognised experts in each unit. He undertook his gastroenterology training at UCLH and the Royal London Hospital, where he worked as a sub-investigator on the GEMINI trial for vedolizumab. Following this he was appointed as an international clinical trials fellow by Robarts research institute. During this fellowship he benefitted from exposure to a wide range of practice patterns and IBD clinical trial methodology under experts in the field: Geert D’Haens at the Academic Medical Centre (Amsterdam), Brian Feagan at the London Health Sciences Centre (Ontario) and William Sandborn at University College San Diego (California). He has participated in, and lead a broad spectrum of original IBD research projects and has been published in several high impact journals (Gut, Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology and Inflammatory Bowel Diseases). In addition, he has co-authored several book chapters on IBD and worked as a ‘Bibliographic Fellow’ on the IOIBD international consensus process regarding treatment targets in IBD (STRIDE). He was awarded the ‘St George’s Young Researcher of the Year Award’ in 2015 and again in 2016, and was runner up for the 2016 ‘BSG Alistair McIntyre Prize’ for improving education by founding the London IBD SpR Training Group. In 2017 he was received a ‘RCP/NIHR CRN Award for Outstanding Research Leadership in the NHS’ and an ECCO Travel Award. He was chosen as an ‘Advanced IBD Fellow’ for the Cornerstones program at DDW 2016 and 2017. He worked with the UK’s national digestive diseases charity (CORE) to update their patient information materials in 2016. He is the trainee member of UK Clinical Research Network: Gastroenterology National Specialty Group and received a 2017 ‘RCP/NIHR CRN Award for Outstanding Research NHS Leadership’. He is currently a Clinical Research Fellow at Guy’s and St Thomas’ NHS Trust, investigating therapeutic drug monitoring for biologic agents in IBD, as part of an MD program at Kings College.   Mark Samaan is currently an IBD Clinical Research Fellow at Guy’s & St Thomas’ Hospital. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Dr Samaan.jpg 35504 Clinical outcomes of Simponi (Golimumab) as a first-line anti-TNF agent in adult patients with moderate to severe ulcerative colitis: Spanish evidence 19:20:00 36410 2 Professor Carlos Taxonera With a medical degree in Spain in 1980, upon his PhD in 1988 at Complutense University of Madrid, Spain, Carlos Taxonera has served as Head of the IBD Unit, Gastroenterology Department, Hospital Clínico, Madrid, from 2003 to the present. He holds the position Staff, Gastroenterology Department, Hospital Clínico, Madrid, between 1986 and 2009 and Senior Staff, Gastroenterology Department, Hospital Clínico, Madrid, 2010 to present. During these years he has focused his scientific interests on the IBD topics and in particular on the treatment with TNF-alpha antagonists in ulcerative colitis, and on the prevention of tuberculosis in patients receiving biological therapy. In the educational area, he works as Associate Professor of Medicine, Department of Medicine, Complutense University, Madrid, from 1987 to present, and as Assistant Professor, Immune Mediated Inflammatory Diseases Postgraduate Master, European University of Madrid, years 2008-2011. He was Deputy Secretary of the Governing Board of the Spanish Society of Gastroenterology, between 1996 and 2001. He published numerous SCI journal papers and book chapters, and worked as a reviewer for many academic journals. He received several academic honors including Best Practices Award for Quality Hospital Clínico in 2006 and the Ernesto Seco Price Award from the Royal Academy of Medicine of Spain in 2012.   Prof Carlos Taxonera, Hospital Clinico San Carlos,Madrid http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Taxonera.jpg 35505 Questions and Discussion 20:00:00 35506 Close 20:15:00 18700 Dr Mark Samaan Mark gained experience as a clinician and researcher at specialist IBD centres in England, The Netherlands, Canada and the US, working under widely recognised experts in each unit. He undertook his gastroenterology training at UCLH and the Royal London Hospital, where he worked as a sub-investigator on the GEMINI trial for vedolizumab. Following this he was appointed as an international clinical trials fellow by Robarts research institute. During this fellowship he benefitted from exposure to a wide range of practice patterns and IBD clinical trial methodology under experts in the field: Geert D’Haens at the Academic Medical Centre (Amsterdam), Brian Feagan at the London Health Sciences Centre (Ontario) and William Sandborn at University College San Diego (California). He has participated in, and lead a broad spectrum of original IBD research projects and has been published in several high impact journals (Gut, Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology and Inflammatory Bowel Diseases). In addition, he has co-authored several book chapters on IBD and worked as a ‘Bibliographic Fellow’ on the IOIBD international consensus process regarding treatment targets in IBD (STRIDE). He was awarded the ‘St George’s Young Researcher of the Year Award’ in 2015 and again in 2016, and was runner up for the 2016 ‘BSG Alistair McIntyre Prize’ for improving education by founding the London IBD SpR Training Group. In 2017 he was received a ‘RCP/NIHR CRN Award for Outstanding Research Leadership in the NHS’ and an ECCO Travel Award. He was chosen as an ‘Advanced IBD Fellow’ for the Cornerstones program at DDW 2016 and 2017. He worked with the UK’s national digestive diseases charity (CORE) to update their patient information materials in 2016. He is the trainee member of UK Clinical Research Network: Gastroenterology National Specialty Group and received a 2017 ‘RCP/NIHR CRN Award for Outstanding Research NHS Leadership’. He is currently a Clinical Research Fellow at Guy’s and St Thomas’ NHS Trust, investigating therapeutic drug monitoring for biologic agents in IBD, as part of an MD program at Kings College.   Mark Samaan is currently an IBD Clinical Research Fellow at Guy’s & St Thomas’ Hospital. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Dr Samaan.jpg 36410 Professor Carlos Taxonera With a medical degree in Spain in 1980, upon his PhD in 1988 at Complutense University of Madrid, Spain, Carlos Taxonera has served as Head of the IBD Unit, Gastroenterology Department, Hospital Clínico, Madrid, from 2003 to the present. He holds the position Staff, Gastroenterology Department, Hospital Clínico, Madrid, between 1986 and 2009 and Senior Staff, Gastroenterology Department, Hospital Clínico, Madrid, 2010 to present. During these years he has focused his scientific interests on the IBD topics and in particular on the treatment with TNF-alpha antagonists in ulcerative colitis, and on the prevention of tuberculosis in patients receiving biological therapy. In the educational area, he works as Associate Professor of Medicine, Department of Medicine, Complutense University, Madrid, from 1987 to present, and as Assistant Professor, Immune Mediated Inflammatory Diseases Postgraduate Master, European University of Madrid, years 2008-2011. He was Deputy Secretary of the Governing Board of the Spanish Society of Gastroenterology, between 1996 and 2001. He published numerous SCI journal papers and book chapters, and worked as a reviewer for many academic journals. He received several academic honors including Best Practices Award for Quality Hospital Clínico in 2006 and the Ernesto Seco Price Award from the Royal Academy of Medicine of Spain in 2012.   Prof Carlos Taxonera, Hospital Clinico San Carlos,Madrid http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Taxonera.jpg 10900 0 Patient Selection and Sequencing Approaches in Advanced Melanoma Patient Selection and Sequencing Approaches in Advanced Melanoma UK uk-UA 17 May 2018 17 May 2018 17 May 2018 17 May 2018 19:00:00 21:00:00 British Summer Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. National Webcast live from Cambridge</div> At this interactive event, you will hear an expert panel share case studies and review strategies for patient selection and effective treatment sequencing when managing advanced melanoma patients using modern immunotherapies and BRAF targeted agents. As a result of attending this event you should be better prepared to: <ul> <li>Evaluate clinical data currently used for treating advanced melanoma</li> <li>Select treatment based on patient and disease characteristics</li> <li>Sequence treatment to optimise patient outcomes</li> <li>Manage challenges associated with treatment selection and sequencing in advanced melanoma</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudamelanoma.pdf">Click here </a>for Prescribing Information</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. National Webcast live from Cambridge At this interactive event, you will hear an expert panel share case studies and review strategies for patient selection and effective treatment sequencing when managing advanced melanoma patients using modern immunotherapies and BRAF targeted agents. As a result of attending this event you should be better prepared to: Evaluate clinical data currently used for treating advanced melanoma Select treatment based on patient and disease characteristics Sequence treatment to optimise patient outcomes Manage challenges associated with treatment selection and sequencing in advanced melanoma Click here for Prescribing Information Master In Progress ONCO-1246506-0009 Date of preparation: April 2018 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage_10900.gif http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage_11086.gif 26 Webconference 26 Webconference 3 Non-Commercial 2 Commercial - Unbranded 35141 Chairman address and welcome 19:00:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 35142 Current treatment landscape Advanced Melanoma 19:10:00 35294 3 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 35143 Case studies: Exploring Patient Selection and Sequencing Approaches in Advanced Melanoma 19:30:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 18672 2 Professor Paul Lorigan Professor Lorigan leads a research based clinical practice, specialising in developing new treatments for malignant melanoma. He is Chair of Melanoma Focus (www.melanomafocus.org), the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He also chairs the EORTC Melanoma Group Advanced Disease Subgroup and previously he chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012.   Professor Paul Lorigan Professor of Medical Oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PLorigan.jpg 35294 3 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 35144 Discussion and Q&A 20:30:00 35890 Closing remarks 20:55:00 18669 1 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 35891 Close meeting 21:00:00 18669 Dr Pippa Corrie - PhD, FRCP Dr Corrie qualified in medicine at Oxford University, having already undertaken a PhD in anticancer drug development. Her specialist and research interests are in melanoma and pancreaticobiliary cancers. From 2012 – 2017, she chaired the NCRI Skin Cancer Clinical Studies Group and is chief investigator of the NIHR portfolio melanoma trials, AVAST-M and INTERIM.  She is the NIHR CRN National Specialty Lead for Cancer: Late Phase and International Trials, as well as CRN Eastern Division 1 (Cancer) Clinical Lead.   Dr Pippa Corrie, PhD, FRCP Consultant Medical Oncologist and Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PCorrie Jan17.JPG 18672 Professor Paul Lorigan Professor Lorigan leads a research based clinical practice, specialising in developing new treatments for malignant melanoma. He is Chair of Melanoma Focus (www.melanomafocus.org), the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He also chairs the EORTC Melanoma Group Advanced Disease Subgroup and previously he chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012.   Professor Paul Lorigan Professor of Medical Oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/PLorigan.jpg 35294 Professor Jeffrey S. Weber - MD, PhD Professor Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), and works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex. He serves as co-director of PCC’s Melanoma Research Program, overseeing work in experimental therapeutics.   Professor Weber’s clinical and research interests primarily lie in the field of immunotherapy for cancer. He works at the forefront of new ideas in immunotherapy for treating patients with melanoma and managing the side effects of these novel therapies.   Professor Weber is the principal investigator of a number of ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute, and his research has been funded by RO1 grants from the NCI for over 23 years.   Professor Weber has published more than 190 articles in the top peer-reviewed journals in his field. He currently sits on the scientific advisory boards of five cancer-related biotechnology companies and numerous cancer institutions and foundations.   Professor Jeffrey S. Weber, MD, PhD Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine NYU Langone Medical Center. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/updated-Weber IO.jpg 11242 0 Contraception 2018 : A Counselling Masterclass Contraception 2018 : A Counselling Masterclass UK uk-UA 05 Jun 2018 05 Jun 2018 05 Jun 2018 05 Jun 2018 12:30:00 13:30:00 British Summer Time This promotional meeting is organised and fully funded by MSD. MSD products will also be discussed at the meeting. <div style="text-align: justify">With such a wide range of contraceptive options available, healthcare professionals face the challenge of matching each patient with the method that is best for her. It is important to address specific concerns of young women to promote compliance. Counselling is essential to provide accurate information about the mechanisms, efficacy and safety of available options and guide her towards the method that will best suit her needs and lifestyle. In this counselling masterclass you will hear from the leading expert, Dr Diana Mansour, about the importance of effective counselling and some strategies to adopt to promote continuation and adherence.</div> <div style="text-align: center"> <a href="http://www.msdproduct.co.uk/api/cerazette.pdf">Click here</a><a href="http://www.msdproduct.co.uk/api/nexplanon.pdf"> </a>for Prescribing Information (Cerazette) <a href="http://www.msdproduct.co.uk/api/marvelon.pdf">Click here </a>for Prescribing Information (Marvelon) <a href="http://www.msdproduct.co.uk/api/mercilon.pdf">Click here </a>for Prescribing Information (Mercilon) <a href="http://www.msdproduct.co.uk/api/nexplanon.pdf">Click here</a> for Prescribing Information (Nexplanon)</div> This promotional meeting is organised and fully funded by MSD. MSD products will also be discussed at the meeting. With such a wide range of contraceptive options available, healthcare professionals face the challenge of matching each patient with the method that is best for her. It is important to address specific concerns of young women to promote compliance. Counselling is essential to provide accurate information about the mechanisms, efficacy and safety of available options and guide her towards the method that will best suit her needs and lifestyle. In this counselling masterclass you will hear from the leading expert, Dr Diana Mansour, about the importance of effective counselling and some strategies to adopt to promote continuation and adherence. Click here for Prescribing Information (Cerazette) Click here for Prescribing Information (Marvelon) Click here for Prescribing Information (Mercilon) Click here for Prescribing Information (Nexplanon) <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align: center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress WOMN-1253117-0000 Date of preparation: April 2018 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage_11242.gif http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage_11242.gif 26 Webconference 26 Webconference 2 Commercial - Unbranded 35826 Contraception 2018 : A Counselling Masterclass 12:30:00 36956 1 Dr Diana Mansour Dr Diana Mansour is a Consultant in Community Gynaecology and Reproductive Healthcare and Head of Clinical Service for Sexual Health in Newcastle upon Tyne, UK. She has been an Associate Clinical Lecturer at Newcastle University since 1997. In addition Dr Mansour is Senior Vice President and Trustee for the Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. Diana is the Lead Officer for FSRH Clinical Standards Committee, Clinical Effectiveness Committee, the FSRH Clinical Studies Group and FSRH Journal. She sits on the FSRH Finance and Investments Committee and Board of Trustees. Dr Mansour is first author to over 90 peer-reviewed publications. She has recently co-written a textbook for general practice and RCOG trainees with Dr Laura Percy and it is entitled 'Contraception Made Easy'. Dr Mansour's areas of expertise include acceptability of contraceptive methods, non-contraceptive benefits of contraception, development of long-term methods of contraception, medical management of heavy menstrual bleeding, menopause and hormone replacement therapy.   Dr Diana Mansour, Consultant in Community Gynaecology and Reproductive Healthcare, Newcastle Hospitals, Community Health. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/D Mansour 2015.JPG 35827 Questions 13:20:00 36956 1 Dr Diana Mansour Dr Diana Mansour is a Consultant in Community Gynaecology and Reproductive Healthcare and Head of Clinical Service for Sexual Health in Newcastle upon Tyne, UK. She has been an Associate Clinical Lecturer at Newcastle University since 1997. In addition Dr Mansour is Senior Vice President and Trustee for the Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. Diana is the Lead Officer for FSRH Clinical Standards Committee, Clinical Effectiveness Committee, the FSRH Clinical Studies Group and FSRH Journal. She sits on the FSRH Finance and Investments Committee and Board of Trustees. Dr Mansour is first author to over 90 peer-reviewed publications. She has recently co-written a textbook for general practice and RCOG trainees with Dr Laura Percy and it is entitled 'Contraception Made Easy'. Dr Mansour's areas of expertise include acceptability of contraceptive methods, non-contraceptive benefits of contraception, development of long-term methods of contraception, medical management of heavy menstrual bleeding, menopause and hormone replacement therapy.   Dr Diana Mansour, Consultant in Community Gynaecology and Reproductive Healthcare, Newcastle Hospitals, Community Health. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/D Mansour 2015.JPG 35828 Close 13:30:00 36956 1 Dr Diana Mansour Dr Diana Mansour is a Consultant in Community Gynaecology and Reproductive Healthcare and Head of Clinical Service for Sexual Health in Newcastle upon Tyne, UK. She has been an Associate Clinical Lecturer at Newcastle University since 1997. In addition Dr Mansour is Senior Vice President and Trustee for the Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. Diana is the Lead Officer for FSRH Clinical Standards Committee, Clinical Effectiveness Committee, the FSRH Clinical Studies Group and FSRH Journal. She sits on the FSRH Finance and Investments Committee and Board of Trustees. Dr Mansour is first author to over 90 peer-reviewed publications. She has recently co-written a textbook for general practice and RCOG trainees with Dr Laura Percy and it is entitled 'Contraception Made Easy'. Dr Mansour's areas of expertise include acceptability of contraceptive methods, non-contraceptive benefits of contraception, development of long-term methods of contraception, medical management of heavy menstrual bleeding, menopause and hormone replacement therapy.   Dr Diana Mansour, Consultant in Community Gynaecology and Reproductive Healthcare, Newcastle Hospitals, Community Health. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/D Mansour 2015.JPG 36956 Dr Diana Mansour Dr Diana Mansour is a Consultant in Community Gynaecology and Reproductive Healthcare and Head of Clinical Service for Sexual Health in Newcastle upon Tyne, UK. She has been an Associate Clinical Lecturer at Newcastle University since 1997. In addition Dr Mansour is Senior Vice President and Trustee for the Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. Diana is the Lead Officer for FSRH Clinical Standards Committee, Clinical Effectiveness Committee, the FSRH Clinical Studies Group and FSRH Journal. She sits on the FSRH Finance and Investments Committee and Board of Trustees. Dr Mansour is first author to over 90 peer-reviewed publications. She has recently co-written a textbook for general practice and RCOG trainees with Dr Laura Percy and it is entitled 'Contraception Made Easy'. Dr Mansour's areas of expertise include acceptability of contraceptive methods, non-contraceptive benefits of contraception, development of long-term methods of contraception, medical management of heavy menstrual bleeding, menopause and hormone replacement therapy.   Dr Diana Mansour, Consultant in Community Gynaecology and Reproductive Healthcare, Newcastle Hospitals, Community Health. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/D Mansour 2015.JPG 11144 0 KEYFOCUS 2018: Bladder Cancer KEYFOCUS 2018: Bladder Cancer UK uk-UA 22 Jun 2018 22 Jun 2018 22 Jun 2018 22 Jun 2018 12:00:00 13:20:00 British Summer Time <div style="text-align: center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. <div>‘With access to new immunotherapies in advanced bladder cancer now established, at KEYFOCUS 2018: Bladder Cancer our keynote speakers will discuss the available treatment options and how these can be adopted into routine clinical practice.´</div> <div style="text-align: left"> </div> <div> <a href="http://www.msdproduct.co.uk/api/keytruda.pdf">Click here </a>for Prescribing Information</div> </div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. ‘With access to new immunotherapies in advanced bladder cancer now established, at KEYFOCUS 2018: Bladder Cancer our keynote speakers will discuss the available treatment options and how these can be adopted into routine clinical practice.´ Click here for Prescribing Information Master In Progress ONCO-1248035-0011 Date of preparation April 2018 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage_11144.gif http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage_11144.gif 26 Webconference 26 Webconference 2 Commercial - Unbranded 35678 Immunotherapy in advanced urothelial carcinoma 12:00:00 36600 1 Professor Winald Gerritsen Prof. Winald Gerritsen, MD, PhD, is medical oncologist at the Radboud Medical Center Nijmegen and an Adjunct Professor at John Hopkins University. Following his medical training at the University of Nijmegen, Dr Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam, where after he worked in different positions at Memorial Sloan Kettering Cancer Center in New York, the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital and the VU Medical Center. He has extensive expertise in translational research with a special interest in tumor-immunology and prostate cancer. Prof. Gerritsen serves as an Advisor at Aglaia Biomedical Ventures B.V, and as a Member of Scientific Advisory Board at ORCA Therapeutics B.V. He serves as a Director of the VUmc Cancer Center Amsterdam. Prof. Gerritsen was the Chairman of the Dutch Society of Gene Therapy.   Professor Winald Gerritsen, Medical Oncologist at the Radboud Medical Center Nijmegen and Adjunct Professor at John Hopkins University http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Gerritsen.jpg 35679 Chemotherapy in advanced urothelial carcinoma 12:30:00 36601 2 Dr Maria De Santis Maria De Santis is a medical oncologist and has recently been appointed Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité University Hospital, Berlin, Germany. Dr De Santis has been an Adjunct Professor for Oncology at the Department of Urology, Medical University of Vienna, Austria since 2016.   Dr De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology, and the German Society for Hematology and Oncology. She also served as a scientific committee member of the American Society of Clinical Oncology for a 3 year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr De Santis is a panel member of the European Association of Urology Scientific Office and Guidelines Board and the International Consultation on Urologic Diseases guideline groups on bladder, testicular and prostate cancer. Her research interests include prostate, bladder, renal and testicular cancer.     Dr Maria De Santis, Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité Medical University Hospital, Berlin, Germany http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Maria De Santis head shot.jpg 35680 Panel discussion 13:00:00 36475 3 Professor Robert Jones <div>Rob is Professor of Clinical Cancer Research at the University of Glasgow and a consultant at the Beatson West of Scotland Cancer Centre. His background includes a molecular biology PhD at the CRUK Beatson Institute and time spent working in Pharmaceutical Research and Development. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research with scientists from the Beatson Institute. He is director of the CR-UK Clinical Trials Unit in Glasgow, and head of the Cancer Clinical Trials Unit for Scotland collaboration (CaCTUS). He is an active member of the UK NCRI Bladder and Kidney Cancer and Prostate Cancer Clinical Studies Groups, and chairs the advanced disease subgroup of the latter.</div> Professor Robert Jones, Professor of Clinical Cancer Research, University of Glasgow, Director, CRUK Clinical Trials Unit, and Honorary Consultant Medical Oncologist, Beatson West of Scotland Cancer Centre http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Rob Jones headshot.jpg 36476 6 Mr Hugh Mostafid Hugh Mostafid trained in urology at Guy's Hospital and the Institute of Urology in London. He is currently consultant urologist and senior lecturer at the Royal Surrey County Hospital as part of a team providing the regional bladder cancer service and one of the few centres in the country performing robotic-assisted radical cystectomy. His main clinical and research interest is bladder cancer. He is a past Chair of Bladder Cancer UK charity, past member of the NCRI Bladder CSG and NICE bladder cancer guidelines group. Currently he is an expert advisor to NICE on bladder cancer and a member of the EAU bladder cancer guideline panel.   Mr Hugh Mostafid, Consultant Urologist and Honorary Senior Lecturer, Royal Surrey County Hospital http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Hugh Mostafid headshot.jpg 36477 4 Dr Simon Crabb Dr Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton and an Honorary Consultant specialising in genitourinary cancers at University Hospital Southampton. His research interests are focussed on the development of novel therapeutic strategies for prostate and bladder cancers. Dr Crabb is Deputy Director of the Southampton Experimental Cancer Medicine Centre and lead for phase I cancer clinical trials. He is a member of the NCRI Clinical Studies Groups for prostate cancer, and bladder and renal cancer, chair of the Advanced Bladder Cancer CSG Subgroup, chair of the Genomics England Clinical Interpretation Partnership for bladder cancer and a member of the Experimental Medicine Expert Review Panel for Cancer Research UK   Dr Simon Crabb, Associate Professor in Medical Oncology at the University of Southampton and Honorary Consultant specialising in genitourinary cancers at University Hospital Southampton http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Simon Crabb headsot.jpg 36478 5 Professor Robert Huddart Professor Robert Huddart is Professor of Urological Cancer at the Institute of Cancer Research in the UK.  He completed a Master of Arts at Oxford, graduating in 1983 as a Bachelor of Medicine and in 1986, a Bachelor of Surgery at the University of London.  He started specialist training in Clinical Oncology at the Royal Marsden Hospital in 1989 and was awarded the Frank Doyle and Rohan Williams medals in the examinations to become a Fellow of the Royal College of Radiologists.  In 1992, he joined the Institute of Cancer Research to complete a PhD in the molecular biology of testicular cancer with Professor Colin Cooper.  After completing his oncology training in 1995, he was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at The Royal Marsden and The Institute of Cancer Research.  In 2007 he was made Reader in Urological Oncology and in 2015, Professor in Urological Cancer.    He has a major research interest in improving the management of bladder cancer, particularly to improve conservative treatment in patients with muscle invasive bladder cancer.  A major focus of his current work is the technical development of radiotherapy, including research on intensity-modulated and image-guided radiotherapy and the application of new imaging techniques. This is alongside work in selecting patients for conservative treatment, use of neoadjuvant and concomitant therapies. His second major research interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorships issues and the genetics of testicular cancer.   He has served as Chair of the National Cancer Research Institute Testis CSG, is current chair of the localised National Cancer Research Institute Bladder cancer sub group and member of the National Cancer Research Institute Bladder CSG and CTRad.  He jointly leads the MSc Oncology course at the Institute of Cancer Research.     Professor Robert Huddart, Professor of Urological Cancer at the Institute of Cancer Research http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/RobertHUDDART headshot.jpg 35681 Close 13:20:00 36600 Professor Winald Gerritsen Prof. Winald Gerritsen, MD, PhD, is medical oncologist at the Radboud Medical Center Nijmegen and an Adjunct Professor at John Hopkins University. Following his medical training at the University of Nijmegen, Dr Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam, where after he worked in different positions at Memorial Sloan Kettering Cancer Center in New York, the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital and the VU Medical Center. He has extensive expertise in translational research with a special interest in tumor-immunology and prostate cancer. Prof. Gerritsen serves as an Advisor at Aglaia Biomedical Ventures B.V, and as a Member of Scientific Advisory Board at ORCA Therapeutics B.V. He serves as a Director of the VUmc Cancer Center Amsterdam. Prof. Gerritsen was the Chairman of the Dutch Society of Gene Therapy.   Professor Winald Gerritsen, Medical Oncologist at the Radboud Medical Center Nijmegen and Adjunct Professor at John Hopkins University http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Gerritsen.jpg 36601 Dr Maria De Santis Maria De Santis is a medical oncologist and has recently been appointed Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité University Hospital, Berlin, Germany. Dr De Santis has been an Adjunct Professor for Oncology at the Department of Urology, Medical University of Vienna, Austria since 2016.   Dr De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology, and the German Society for Hematology and Oncology. She also served as a scientific committee member of the American Society of Clinical Oncology for a 3 year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr De Santis is a panel member of the European Association of Urology Scientific Office and Guidelines Board and the International Consultation on Urologic Diseases guideline groups on bladder, testicular and prostate cancer. Her research interests include prostate, bladder, renal and testicular cancer.     Dr Maria De Santis, Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité Medical University Hospital, Berlin, Germany http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Maria De Santis head shot.jpg 36475 Professor Robert Jones <div>Rob is Professor of Clinical Cancer Research at the University of Glasgow and a consultant at the Beatson West of Scotland Cancer Centre. His background includes a molecular biology PhD at the CRUK Beatson Institute and time spent working in Pharmaceutical Research and Development. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research with scientists from the Beatson Institute. He is director of the CR-UK Clinical Trials Unit in Glasgow, and head of the Cancer Clinical Trials Unit for Scotland collaboration (CaCTUS). He is an active member of the UK NCRI Bladder and Kidney Cancer and Prostate Cancer Clinical Studies Groups, and chairs the advanced disease subgroup of the latter.</div> Professor Robert Jones, Professor of Clinical Cancer Research, University of Glasgow, Director, CRUK Clinical Trials Unit, and Honorary Consultant Medical Oncologist, Beatson West of Scotland Cancer Centre http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Rob Jones headshot.jpg 36477 Dr Simon Crabb Dr Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton and an Honorary Consultant specialising in genitourinary cancers at University Hospital Southampton. His research interests are focussed on the development of novel therapeutic strategies for prostate and bladder cancers. Dr Crabb is Deputy Director of the Southampton Experimental Cancer Medicine Centre and lead for phase I cancer clinical trials. He is a member of the NCRI Clinical Studies Groups for prostate cancer, and bladder and renal cancer, chair of the Advanced Bladder Cancer CSG Subgroup, chair of the Genomics England Clinical Interpretation Partnership for bladder cancer and a member of the Experimental Medicine Expert Review Panel for Cancer Research UK   Dr Simon Crabb, Associate Professor in Medical Oncology at the University of Southampton and Honorary Consultant specialising in genitourinary cancers at University Hospital Southampton http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Simon Crabb headsot.jpg 36478 Professor Robert Huddart Professor Robert Huddart is Professor of Urological Cancer at the Institute of Cancer Research in the UK.  He completed a Master of Arts at Oxford, graduating in 1983 as a Bachelor of Medicine and in 1986, a Bachelor of Surgery at the University of London.  He started specialist training in Clinical Oncology at the Royal Marsden Hospital in 1989 and was awarded the Frank Doyle and Rohan Williams medals in the examinations to become a Fellow of the Royal College of Radiologists.  In 1992, he joined the Institute of Cancer Research to complete a PhD in the molecular biology of testicular cancer with Professor Colin Cooper.  After completing his oncology training in 1995, he was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at The Royal Marsden and The Institute of Cancer Research.  In 2007 he was made Reader in Urological Oncology and in 2015, Professor in Urological Cancer.    He has a major research interest in improving the management of bladder cancer, particularly to improve conservative treatment in patients with muscle invasive bladder cancer.  A major focus of his current work is the technical development of radiotherapy, including research on intensity-modulated and image-guided radiotherapy and the application of new imaging techniques. This is alongside work in selecting patients for conservative treatment, use of neoadjuvant and concomitant therapies. His second major research interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorships issues and the genetics of testicular cancer.   He has served as Chair of the National Cancer Research Institute Testis CSG, is current chair of the localised National Cancer Research Institute Bladder cancer sub group and member of the National Cancer Research Institute Bladder CSG and CTRad.  He jointly leads the MSc Oncology course at the Institute of Cancer Research.     Professor Robert Huddart, Professor of Urological Cancer at the Institute of Cancer Research http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/RobertHUDDART headshot.jpg 36476 Mr Hugh Mostafid Hugh Mostafid trained in urology at Guy's Hospital and the Institute of Urology in London. He is currently consultant urologist and senior lecturer at the Royal Surrey County Hospital as part of a team providing the regional bladder cancer service and one of the few centres in the country performing robotic-assisted radical cystectomy. His main clinical and research interest is bladder cancer. He is a past Chair of Bladder Cancer UK charity, past member of the NCRI Bladder CSG and NICE bladder cancer guidelines group. Currently he is an expert advisor to NICE on bladder cancer and a member of the EAU bladder cancer guideline panel.   Mr Hugh Mostafid, Consultant Urologist and Honorary Senior Lecturer, Royal Surrey County Hospital http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Hugh Mostafid headshot.jpg 12696 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 18 Mar 2019 18 Mar 2019 18 Mar 2019 18 Mar 2019 12:30:00 14:00:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. </div> <div>An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC</div> <div> OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00105 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Live ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 38071 Welcome and Introductions 12:30:00 20213 1 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 38072 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 12:35:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 38073 Q & A 13:30:00 20213 1 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 38075 Close 14:00:00 20213 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 12520 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 19 Mar 2019 19 Mar 2019 19 Mar 2019 19 Mar 2019 19:00:00 20:30:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.</div> <div> </div> <div>An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC. OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div> </div> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC. OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00108 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Live ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 37887 Welcome and Introductions 19:00:00 59830 1 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 37888 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 19:05:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 37889 Q & A 20:00:00 59830 1 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 37891 Close 20:30:00 59830 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 12540 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 20 Mar 2019 20 Mar 2019 20 Mar 2019 20 Mar 2019 19:00:00 20:30:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.</div> <div> </div> <div> An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC</div> <div> OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00111 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Live ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 38066 Welcome and Introductions 19:00:00 60281 1 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 38067 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 19:05:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 38068 Discussion and questions. 20:00:00 60281 1 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 38069 Close 20:30:00 60281 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG

Rating:

18th Mar 201912:30 - 14:00

The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response

For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
Register now

Rating:

19th Mar 201919:00 - 20:30

The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response

For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
Register now

Rating:

20th Mar 201919:00 - 20:30

The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response

For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications click hereThis promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the... Learn more »
Register now

Past Events

Watch events on demand, download related materials and catch up on selected highlights from past events

No events listed at present, please check again soon.

GB-NON-00477 | Date of preparation: February 2019